168,664 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 168,664 shares of the biopharmaceutical company’s stock, valued at approximately $50,773,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALNY. iA Global Asset Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 979.5% in the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after acquiring an additional 16,133 shares during the period. SCS Capital Management LLC acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth $34,784,000. Hussman Strategic Advisors Inc. acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $2,505,000. Hsbc Holdings PLC grew its position in Alnylam Pharmaceuticals by 22.6% during the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after purchasing an additional 16,503 shares during the last quarter. Finally, Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth $243,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ALNY shares. Barclays reduced their target price on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a report on Monday, August 3rd. Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target on the stock in a report on Monday, August 3rd. Bank of America dropped their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research report on Tuesday, July 14th. Weiss Ratings raised Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. decreased their price objective on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $386.62.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $242.61 on Thursday. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The stock has a market cap of $32.46 billion, a PE ratio of 45.09 and a beta of 0.30. The firm’s fifty day simple moving average is $269.15 and its 200-day simple moving average is $298.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business’s revenue for the quarter was up 66.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.51) earnings per share. Analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.